Dichotomous role of the serine/threonine kinase MAP4K4 in pancreatic ductal adenocarcinoma onset and metastasis through control of AKT and ERK pathways
The Journal of Pathology · 2024
DOI: 10.1002/path.6248 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology, 2024. Verfasst von Amelie Juin und 2 weiteren Autor:innen. Beteiligte Einrichtung: CRUK Beatson Institute, Glasgow, UK. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Cancer Research UK core grants to the Beatson Institute.
Abstract (Originalsprache)
MAP4K4 is a serine/threonine kinase of the STE20 family involved in the regulation of actin cytoskeleton dynamics and cell motility. It has been proposed as a target of angiogenesis and inhibitors show potential in cardioprotection. MAP4K4 also mediates cell invasion in vitro , is overexpressed in various types of cancer, and is associated with poor patient prognosis. Recently, MAP4K4 has been shown to be overexpressed in pancreatic cancer, but its role in tumour initiation, progression, and metastasis is unknown. Here, using the Kras G12D Trp53 R172H Pdx1‐ Cre (KPC) mouse model of pancreatic ductal adenocarcinoma (PDAC), we show that deletion of Map4k4 drives tumour initiation and progression. Moreover, we report that the acceleration of tumour onset is also associated with an overactivation of ERK and AKT, two major downstream effectors of KRAS, in vitro and in vivo . In contrast to the accelerated tumour onset caused by loss of MAP4K4, we observed a reduction in metastatic burden with both the KPC model and in an intraperitoneal transplant assay indicating a major role of MAP4K4 in metastatic seeding. In summary, our study sheds light on the dichotomous role of MAP4K4 in the initiation of PDAC onset, progression, and metastatic dissemination. It also identifies MAP4K4 as a possible druggable target against pancreatic cancer spread, but with the caveat that targeting MAP4K4 might accelerate early tumorigenesis. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CRUK Beatson Institute, Glasgow, UK.
- School of Cancer Sciences, University of Glasgow, Glasgow, UK.
- Department of Biochemistry, University of Cambridge, Cambridge, UK.
ORCID-Profile: Amelie Juin, Laura M Machesky
Förderung
- Cancer Research UK
- Cancer Research UK core grants to the Beatson Institute
Zitieren
APA
Juin, A., Spence, H. J., & Machesky, L. M. (2024). Dichotomous role of the serine/threonine kinase MAP4K4 in pancreatic ductal adenocarcinoma onset and metastasis through control of AKT and ERK pathways. The Journal of Pathology. https://doi.org/10.1002/path.6248
Vancouver
Juin A, Spence HJ, Machesky LM. Dichotomous role of the serine/threonine kinase MAP4K4 in pancreatic ductal adenocarcinoma onset and metastasis through control of AKT and ERK pathways. The Journal of Pathology. 2024. doi:10.1002/path.6248
BibTeX
@article{Juin2024,
author = {Juin, Amelie and Spence, Heather J and Machesky, Laura M},
title = {Dichotomous role of the serine/threonine kinase MAP4K4 in pancreatic ductal adenocarcinoma onset and metastasis through control of AKT and ERK pathways},
journal = {The Journal of Pathology},
year = {2024},
doi = {10.1002/path.6248}
}
EUVIMED